title: Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence.
abstract: Gefitinib, an epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI), has been approved in Japan for the treatment of patients with advanced non-small-cell lung cancer (NSCLC) based on Phase II clinical trials since 2002. Erlotinib, another EGFR-TKI, was also approved a few years thereafter. In 2004, activating mutations in the EGFR gene were discovered to be a predictive biomarker for EGFR-TKI treatment, and gefitinib, which is not effective for patients with EGFR wild-type NSCLC, has since been used only in patients with EGFR-mutated NSCLC. In contrast, erlotinib is potentially effective for the treatment of EGFR wild-type NSCLC. Similar to gefitinib, erlotinib is also effective for EGFR-mutated NSCLC and has been used as an initial treatment for patients with advanced EGFR-mutated NSCLC. Both gefitinib and erlotinib can be used in a Japanese clinical setting. The approved daily dose of erlotinib (150 mg) is equal to the maximum tolerated dose of erlotinib. In contrast, the daily dose of gefitinib has been set at 250 mg, which is approximately one-third of the maximum tolerated dose of gefitinib. Accordingly, a higher serum concentration can be achieved using erlotinib, compared with gefitinib. This advantage can be applied to the treatment of central nervous system metastases (brain metastasis and carcinomatous meningitis), the treatment of which is complicated by the difficulty drugs have penetrating the blood-brain barrier. Although patients with EGFR-mutated NSCLC respond dramatically to EGFR-TKIs, some patients have a poor response and the majority eventually undergo disease progression. To overcome such resistance, several novel treatment strategies, such as combination therapy and next-generation EGFR-TKIs, have been attempted.
authors.affiliation: Department of Genome Biology, Kindai University Faculty of Medicine, Osaka, Japan.
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Togashi
authors.affiliation: Department of Genome Biology, Kindai University Faculty of Medicine, Osaka, Japan ; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan ; Department of Medical Oncology, Kishiwada Municipal Hospital, Osaka, Japan.
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Hayashi
authors.affiliation: Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Nakagawa
authors.affiliation: Department of Genome Biology, Kindai University Faculty of Medicine, Osaka, Japan.
authors.forename: Kazuto
authors.initials: K
authors.lastname: Nishio
mesh_terms: D044466:Asian People; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D020714:Maximum Tolerated Dose; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D011799:Quinazolines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D000077156:Gefitinib
keywords: EGFR mutation; epidermal growth factor receptor tyrosine kinase inhibitor; erlotinib; non-small-cell lung cancer
references.citation: J Clin Oncol. 2003 Jun 15;21(12):2237-46
references.pmid: 12748244
references.citation: N Engl J Med. 2009 Sep 3;361(10):958-67
references.pmid: 19692684
references.citation: J Thorac Oncol. 2013 Aug;8(8):1069-74
references.pmid: 23804027
references.citation: N Engl J Med. 2009 Sep 3;361(10):947-57
references.pmid: 19692680
references.citation: Cancer Sci. 2007 Dec;98(12):1817-24
references.pmid: 17888036
references.citation: N Engl J Med. 2005 Jul 14;353(2):123-32
references.pmid: 16014882
references.citation: Nat Biotechnol. 2005 Mar;23(3):329-36
references.pmid: 15711537
references.citation: Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8272-7
references.pmid: 10890904
references.citation: Oncologist. 2005 Aug;10(7):461-6
references.pmid: 16079312
references.citation: Clin Cancer Res. 2011 Oct 1;17(19):6298-303
references.pmid: 21856766
references.citation: Lancet Oncol. 2013 Sep;14(10):981-8
references.pmid: 23883922
references.citation: Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44
references.pmid: 16467097
references.citation: J Clin Oncol. 2010 Jun 10;28(17):e273-4
references.pmid: 20385983
references.citation: Clin Cancer Res. 2006 Jul 1;12(13):3908-14
references.pmid: 16818686
references.citation: Cancer. 2013 Aug 1;119(15):2754-64
references.pmid: 23661337
references.citation: J Clin Oncol. 2008 Sep 10;26(26):4268-75
references.pmid: 18626007
references.citation: J Thorac Oncol. 2010 Jul;5(7):950-5
references.pmid: 20479691
references.citation: N Engl J Med. 2006 Dec 14;355(24):2542-50
references.pmid: 17167137
references.citation: J Clin Oncol. 2006 Mar 10;24(8):1295-304
references.pmid: 16525185
references.citation: JAMA. 2003 Oct 22;290(16):2149-58
references.pmid: 14570950
references.citation: Ann Oncol. 2013 Jun;24(6):1615-22
references.pmid: 23456778
references.citation: Cancer Treat Rev. 2014 Feb;40(1):93-101
references.pmid: 23829935
references.citation: Clin Lung Cancer. 2010 Jan;11(1):51-6
references.pmid: 20085868
references.citation: J Mol Diagn. 2006 Jul;8(3):335-41
references.pmid: 16825506
references.citation: Nat Rev Cancer. 2010 Nov;10(11):760-74
references.pmid: 20966921
references.citation: Clin Cancer Res. 2011 Mar 1;17(5):1169-80
references.pmid: 21248300
references.citation: Bioorg Med Chem Lett. 2001 Jul 23;11(14):1911-4
references.pmid: 11459659
references.citation: Sci Transl Med. 2013 Dec 18;5(216):216ra177
references.pmid: 24353160
references.citation: J Thorac Oncol. 2010 Jan;5(1):99-104
references.pmid: 19898258
references.citation: Clin Cancer Res. 2006 Apr 15;12(8):2538-44
references.pmid: 16638863
references.citation: J Clin Oncol. 2011 Jul 1;29(19):e588-90
references.pmid: 21502555
references.citation: J Clin Oncol. 2010 Jan 10;28(2):357-60
references.pmid: 19949011
references.citation: J Clin Oncol. 2007 Apr 20;25(12):1545-52
references.pmid: 17442998
references.citation: Clin Cancer Res. 2013 Apr 15;19(8):2240-7
references.pmid: 23470965
references.citation: N Engl J Med. 2010 Jun 24;362(25):2380-8
references.pmid: 20573926
references.citation: J Clin Oncol. 2013 Aug 10;31(23):2895-902
references.pmid: 23835707
references.citation: J Clin Oncol. 2009 Mar 20;27(9):1394-400
references.pmid: 19224850
references.citation: N Engl J Med. 2002 Jan 10;346(2):92-8
references.pmid: 11784875
references.citation: Cancer Res. 1997 Nov 1;57(21):4838-48
references.pmid: 9354447
references.citation: Cancer Res. 2005 Aug 15;65(16):7276-82
references.pmid: 16105816
references.citation: J Clin Oncol. 2005 Sep 1;23(25):6207-19
references.pmid: 16135488
references.citation: Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11
references.pmid: 15329413
references.citation: Oncologist. 2009 Feb;14(2):137-47
references.pmid: 19190239
references.citation: Clin Cancer Res. 2009 Jan 15;15(2):460-7
references.pmid: 19147750
references.citation: Lancet Oncol. 2011 Aug;12(8):735-42
references.pmid: 21783417
references.citation: J Cell Mol Med. 2010 Jan;14(1-2):51-69
references.pmid: 20015198
references.citation: Lancet Oncol. 2010 Feb;11(2):121-8
references.pmid: 20022809
references.citation: J Clin Oncol. 2016 Sep 20;34(27):3248-57
references.pmid: 27022112
references.citation: Ann Oncol. 2007 Feb;18(2):317-23
references.pmid: 17079694
references.citation: J Clin Oncol. 2005 Sep 1;23(25):5892-9
references.pmid: 16043829
references.citation: J Clin Oncol. 2005 Apr 10;23(11):2513-20
references.pmid: 15738541
references.citation: CA Cancer J Clin. 2012 Jul-Aug;62(4):220-41
references.pmid: 22700443
references.citation: Lancet. 2011 May 28;377(9780):1846-54
references.pmid: 21621716
references.citation: Ann Oncol. 2015 Sep;26(9):1883-1889
references.pmid: 26105600
references.citation: N Engl J Med. 2005 Feb 24;352(8):786-92
references.pmid: 15728811
references.citation: Clin Cancer Res. 2008 Nov 1;14(21):6963-73
references.pmid: 18980991
references.citation: Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37
references.pmid: 16257339
references.citation: Lung Cancer. 2011 Oct;74(1):98-102
references.pmid: 21377230
references.citation: Science. 2004 Jun 4;304(5676):1497-500
references.pmid: 15118125
references.citation: Clin Cancer Res. 2007 Jun 1;13(11):3413-22
references.pmid: 17545550
references.citation: Lancet Oncol. 2013 Jul;14(8):777-86
references.pmid: 23782814
references.citation: Ann Oncol. 2005 Jul;16(7):1081-6
references.pmid: 15851406
references.citation: Cancer Chemother Pharmacol. 2008 Mar;61(3):489-96
references.pmid: 17483950
references.citation: J Clin Oncol. 2012 Jun 10;30(17):2063-9
references.pmid: 22547605
references.citation: Cancer Treat Rev. 2013 Dec;39(8):839-50
references.pmid: 23768755
references.citation: N Engl J Med. 2013 Jun 20;368(25):2385-94
references.pmid: 23724913
references.citation: Lancet Oncol. 2010 Jun;11(6):521-9
references.pmid: 20493771
references.citation: Nature. 2007 Aug 2;448(7153):561-6
references.pmid: 17625570
references.citation: Ann Oncol. 2012 Nov;23(11):2914-2919
references.pmid: 22776705
references.citation: Cancer. 2005 Jun 1;103(11):2344-8
references.pmid: 15844174
references.citation: J Clin Oncol. 2014 Jun 20;32(18):1902-8
references.pmid: 24841974
references.citation: Cancer Chemother Pharmacol. 2012 Sep;70(3):399-405
references.pmid: 22806307
references.citation: J Thorac Oncol. 2012 Nov;7(11):1722-7
references.pmid: 23059777
references.citation: Cancer. 2013 Dec 15;119(24):4325-32
references.pmid: 24105277
references.citation: Ann Thorac Med. 2013 Oct;8(4):204-8
references.pmid: 24250733
references.citation: Cancer Metastasis Rev. 2012 Dec;31(3-4):807-14
references.pmid: 22736441
references.citation: Lancet. 2009 Oct 24;374(9699):1432-40
references.pmid: 19767093
references.citation: Lung Cancer. 2012 Sep;77(3):556-60
references.pmid: 22677429
references.citation: Jpn J Clin Oncol. 2011 Aug;41(8):959-63
references.pmid: 21715361
references.citation: N Engl J Med. 2004 May 20;350(21):2129-39
references.pmid: 15118073
references.citation: J Thorac Oncol. 2013 Mar;8(3):346-51
references.pmid: 23407558
references.citation: Lancet Oncol. 2012 Mar;13(3):247-55
references.pmid: 22341744
references.citation: Oncologist. 2003;8(4):303-6
references.pmid: 12897327
references.citation: Ann Oncol. 2003 Jun;14(6):922-30
references.pmid: 12796031
references.citation: J Thorac Oncol. 2013 Sep;8(9):1148-55
references.pmid: 23945384
references.citation: J Pharmacol Exp Ther. 2012 Nov;343(2):342-50
references.pmid: 22888144
references.citation: Lancet Oncol. 2012 Nov;13(11):1161-70
references.pmid: 23078958
references.citation: Lancet Oncol. 2012 Mar;13(3):239-46
references.pmid: 22285168
references.citation: J Clin Oncol. 2009 Oct 20;27(30):5080-7
references.pmid: 19738125
references.citation: J Clin Oncol. 2010 Dec 20;28(36):5247-56
references.pmid: 21079146
references.citation: J Clin Oncol. 2011 Jul 20;29(21):2866-74
references.pmid: 21670455
references.citation: Jpn J Clin Oncol. 2013 Jun;43(6):629-35
references.pmid: 23599349
references.citation: CA Cancer J Clin. 2013 Jan;63(1):11-30
references.pmid: 23335087
references.citation: Cancer. 2011 Jan 1;117(1):143-51
references.pmid: 20803614
references.citation: Lung Cancer. 2013 Oct;82(1):109-14
references.pmid: 23910906
references.citation: Clin Cancer Res. 2006 Jul 1;12(13):3915-21
references.pmid: 16818687